Publication | Open Access

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects

Epoxyketone-based Proteasome InhibitorsMedicinal ChemistryBone-anabolic ActivityPharmacologyPharmacotherapyBioavailable OprozomibAnti-cancer AgentDrug DevelopmentMedicineDrug Discovery